The first wave of NASH candidates includes: Obeticholic acid (Intercept Pharmaceuticals) Intercepts application for accelerated approval for obeticholic acid (OCA) was denied by the FDA on June 29, 2020, contrary to expectations
Unlike traditional pricing models where cost climbs with dose escalation, PlexusDx charges one flat monthly rate regardless of how your therapy evolves
By mimicking the action of GLP-1, it helps regulate insulin secretion and reduce glucagon release, leading to improved blood sugar control
Orders for oral semaglutide (Rybelsus) were excluded due to low frequency and its limited indication for weight loss
Look for sourcing from a licensed US compounding pharmacy, a licensed provider who screens candidacy, honest framing that AOD 9604 is not FDA-approved, and progress measured by body composition and labs